Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
The regimen also lowered A1C by up to 2.9% and moved into Phase 3 planning after meeting the study's main goals.
- On Wednesday, Eli Lilly reported its experimental combination regimen showed greater weight loss than tirzepatide alone in a mid-stage trial targeting patients with obesity and Type 2 diabetes.
- The combination treatment links eloralintide with tirzepatide, hitting three hormonal pathways including amylin, and yielded 23.3% weight loss in the 48-week Phase 2 trial.
- Adding 3-milligram of eloralintide to tirzepatide led to 17% weight loss over 16 weeks, while the combo treatment reduced A1C by up to 2.9% versus 2.4% for tirzepatide alone.
- Patients on the combination regimen discontinued treatment at rates of 10.8% to 27% due to side effects, though Ken Custer, president of Lilly Cardiometabolic Health, cautioned against over-interpreting these rates.
- Lilly plans to advance the combination product into Phase 3 studies by the end of 2026, positioning the regimen as a competitor to Novo's next-generation obesity treatment CagriSema.
14 Articles
14 Articles
Eli Lilly stated on Wednesday (30) that her combined weight loss experimental drug exceeded Zepbound, her highly successful product, in a direct comparative study, intensifying competition with the Danish rival Novo Nordisk for new and more effective anti-obesity therapies. Pharmaceuticals based in Indianapolis said that patients with diabetes who received the highest dose of EloraTZP, a combination of tyrzepatide with the experimental eloralint…
Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study
Eli Lilly & Co. said a new drug combination helped people with diabetes lose as much as 23% of their weight, more than other medicines in similar studies, suggesting it has the potential to be the drugmaker’s strongest obesity shot to date.
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Eli Lilly said on Wednesday its experimental combination weight-loss drug outperformed its blockbuster Zepbound in a head-to-head trial, intensifying the competition with Danish rival Novo Nordisk for new, more effective obesity therapies.
Coverage Details
Bias Distribution
- 80% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
